Sponsored by Nektar Therapeutics
This activity is not certified for credit.
Wednesday, September 6
Opioids are considered the most effective therapeutic option for pain, but come with unwanted CNS side effects including dizziness, sleepiness, respiratory depression and the potential for abuse and addiction. Opioid abuse remains a major public health problem, despite heightened awareness among healthcare professionals, patients, the public and the advent of abuse-deterrent formulations.
In this symposium, two nationally recognized pain specialists will examine this dilemma from both a clinical and a pharmacologic perspective. They will discuss how rapid entry into the brain leads to euphoria: a key risk factor in making currently available opioids attractive for abuse. Further, they will describe how the investigational agent, NKTR-181, a new chemical entity characterized by slow entry into the brain, may address the still unmet need of providing effective pain relief without the high levels of euphoria that often cause abuse and addiction.
At the conclusion of this program, participants will be able to:
Jeffrey Gudin, MD
Richard Rauck, MD
Pre-registration not required. Please arrive at least 15 minutes prior to start time.
Posted on August 16, 2017